Anupam Rasayan — From an LOI Spree to an Acquisition Spree

The State of Play

Anupam Rasayan makes complicated molecules to order — the multi-step chemistry that global agrochemical and pharmaceutical companies would rather outsource to a trusted specialist than run themselves. For two years (FY24 and FY25) the business sat in a holding pattern: revenue flat, profit squeezed, a big new factory built but not yet full. Then the year ended March 2026 broke the pattern — revenue jumped 65% to ₹2,365 crore and profit recovered to ₹222 crore — and management used the moment not to consolidate but to go shopping, signing two acquisitions (a US chemicals plant and a controlling stake in a listed pharma company) in the space of six months. The stock is priced for the optimism this implies — about 89 times earnings and 4.5 times book — even though returns on capital remain thin (a 7.4% ROCE) and free cash flow is still negative.

The Company

Founded in 1984 and listed only in March 2021, Anupam is a custom-synthesis (or “CSM”) specialty-chemicals manufacturer based in Surat, Gujarat. The model is business-to-business: customers — mostly multinational agro and pharma majors — bring a molecule they need made, and Anupam builds the multi-step process to make it, often under multi-year contracts. About 91% of revenue is “Life Science Specialty Chemicals,” and inside that, by the most recent breakdown, agrochemicals are the largest slice (around 55%, down from 76% a few years ago), with pharmaceuticals (~20%) and performance materials (~18%) the fast-growing newer legs. Exports are roughly 58% of revenue, with Europe, Japan and increasingly the US the key markets.

It is a capital- and inventory-hungry business. The cash-conversion cycle runs to a startling 377 days (inventory alone is ~490 days), partly because customers underwrite inventory that then sits through a downturn. Borrowings have climbed steadily — from ₹822 crore (March 2023) to ₹1,867 crore (March 2026) — and free cash flow has been negative in most recent years as capex ran ahead of earnings.

Promoters held a steady ~61% until a one-step cut to 59.07% in the September 2025 quarter. The more striking ownership shift is below them: domestic institutions have almost completely exited (from 3.74% to 0.35% over three years), foreign holdings have drifted lower and choppier, and the public’s share has risen every quarter to 33.65%. (The snapshot names no promoters and gives no CAGR figures, so this chronicle relies on the annual reports and calls for the qualitative story.)

The Story So Far

Anupam’s recent arc is a clean three-act structure: a confident boom, a two-year digestion of a big capex bill during a bad agrochemical cycle, and then a debt-funded growth sprint built on acquisitions.

FY23 — the high-water mark

The FY23 annual report is the most confident document in the set. Revenue rose 49% to ₹1,610 crore (consolidated, ₹16,105 million), EBITDA margin a healthy 27%, profit up 42%. The chairman leaned hard on the structural tailwind:

“With China+1 and Europe+1… and Indian specialty chemical manufacturing gaining global ground, the potential for growth is boundless.” — Dr. Kiran C. Patel, Chairman

Two strategic moves anchored the year: the integration of Tanfac Industries (a fluorination raw-material maker — backward integration into HF and KF), and the commitment of a large ₹6,700 million capex programme for three new multipurpose plants, of which barely ₹644 million had been spent by year-end. The contracted order book — signed LOIs to be delivered over 5–7 years — stood at about ₹54,800 million. The thesis was simple: build the plants, fill them with the order book, earn 20%-plus returns.

FY24 — the cycle turns, the order book doesn’t

A year later the swagger was gone. Revenue fell 7% to ₹1,475 crore — the first de-growth — as the agrochemical industry destocked and demand went soft. Profit dropped to ₹167 crore. Management’s narrative pivoted from celebrating growth to emphasising visibility: even as the P&L sagged, the company commercialised 17 new molecules and signed a cluster of large new contracts (several big Japanese LOIs), pushing the order book from ₹54,800 million to about ₹89,000 million. The capex programme neared completion (₹4,824 million of the ₹6,700 million now spent), and the company raised ₹5,500 million through a preferential allotment, using part of it to repay ₹2,490 million of long-term debt. The new strategic refrain: diversify away from agrochemicals (toward pharma and polymers), and lean into Japan.

FY25 — the gap year

FY25 was the “capex done, now waiting” year. Revenue stayed soft (around ₹1,437 crore), and although EBITDA margin actually firmed toward 28%, profit slipped again to ₹160 crore — because the now-completed plants brought a full load of depreciation and interest with them (finance cost rose to ₹112 crore, depreciation to ₹102 crore). Short-term borrowings and payables ballooned as working capital swelled. The fluorination push deepened (Tanfac consolidated as a material subsidiary, a new wholly-owned fluorination vehicle funded). The ₹89,000 million order book sat there as the bridge management was implicitly counting on. (A note on sourcing: the FY25 report extract did not capture the chairman’s and MD’s letters, so FY25’s management framing is inferred from the financial statements rather than quoted.)

Q2 FY26 (call of 17 October 2025) — the rebound arrives, loudly

The September 2025 quarter was the inflection. Revenue hit ₹731 crore, up 149% year-on-year — “one of the best quarters” — and first-half revenue had already surpassed the entire prior year. Management guided to over 50% revenue growth for FY26, a rich order book (~₹14,646 crore) expected to contribute ~₹450 crore that year, and a net-debt baseline of ₹730 crore. But two cautions were buried in the detail that later quarters would vindicate: roughly 25–30% of the quarter’s revenue came from liquidating older inventory at lower margins (so the quarter would be hard to repeat), and management gently walked back an earlier 26–28% margin aspiration to “around 25%, plus or minus one percentage point.” It also flagged it was “actively looking for assets” — the first hint of what was coming.

December 2025 — the first acquisition (Jayhawk)

In a special call on 15 December, Anupam announced it would buy 100% of Jayhawk Fine Chemicals, a Kansas-based maker of high-value di-anhydrides and polyimide intermediates (feeding semiconductors, EVs, electronics), from a private-equity owner exiting at the end of its fund life. The economics: ~US$134 million enterprise value, about 9 times the target’s CY24 EBITDA. Cleverly, Anupam itself put in only US$40 million; about US$110 million came from a large global investment firm taking non-voting Class B shares — a structure that let Anupam fully consolidate Jayhawk while limiting its own cash and debt outlay. The pitch was onshore US manufacturing, forward integration (Tanfac makes the raw material, Jayhawk sits close to the end customer), and a tailwind from the US Biosecure Act steering pharma away from Chinese suppliers. EPS-accretive “from day one,” closing expected late January.

Q3 FY26 (call of 14 February 2026) — the inventory boost rolls off

The December quarter showed the other side of Q2’s blockbuster: revenue cooled sequentially to ₹512 crore (still up 31% year-on-year) as the one-off inventory liquidation dropped out — but margin recovered to the promised 25%. Nine-month revenue was up 84%. Pharma (+85%) and the polymer/performance-material leg (+245%) were growing fast off small bases; Japan was ~17% of the quarter. Management nudged its working-capital promise out again — “around 180 days or below” was now a FY27 target, from ~250 days currently.

Q4 and FY26 (call of 25 May 2026) — the second acquisition, and the scorecard

The year closed with FY26 revenue at ₹2,384 crore (+65%), EBITDA margin 23%, profit ₹222 crore — and a second deal. Anupam announced it would acquire a 43.3%–48.2% stake in Bliss GVS Pharma, a listed finished-dosage (FDF) and CDMO maker with US-FDA/EU-GMP approvals running at just ~30% utilisation, funded largely by ~₹300 crore of NCDs in a wholly-owned subsidiary, plus an open offer. An analyst captured the shift bluntly:

“Moving from an LOI spree to an acquisition spree.” — analyst question, paraphrased; management reframed it as building a vertically integrated platform across four independent entities (Anupam, Tanfac, Jayhawk, Bliss).

Pro forma, the four entities together would be a >₹4,000 crore revenue, ~₹834 crore EBITDA group. Crucially, management declared the capital-spending chapter largely over: the ₹315 crore spent in FY26 was “the last leg,” all plants are commercialised, and only ~₹50–75 crore of annual maintenance capex is envisaged. It guided the standalone business to 20–25% (up to 30%) growth over the next 3–5 years, with peak revenue of ~₹3,500 crore achievable on the existing asset base — i.e. room to roughly double without new plants.

How did the promises hold up? Mixed, and worth stating plainly:

• FY26 “>50% revenue growth” → delivered (+65%).
• Margin “~25% ±1pp” → partially; Q3 hit 25% but Q4 slipped to 22%, FY26 landed at 23%.
• Working-capital days toward 200 → not yet; still ~240–250 ex-Jayhawk, pushed to a FY27 promise.
• Net debt ₹730 crore baseline → rose materially to ~₹1,100 crore (and heading to ~₹1,400–1,500 crore with Bliss) — driven entirely by the two acquisitions, not operations.

Where Things Stand

As of the May 2026 call, Anupam is a recovering custom-synthesis business that has chosen to grow by acquisition. The core agrochemical cycle has turned up, pharma and polymers are scaling, the big organic capex bill is paid, and a large contracted order book remains the visibility anchor. Against that, the picture has genuine tension: reported returns are still low (ROCE ~7%, ROE ~5.5%), free cash flow remains negative, leverage is climbing as the acquisitions are debt-funded, and an unusually low recent effective tax rate is flattering the headline profit. The forward story management is selling is integration — four entities, from fluorine raw materials (Tanfac) through US performance materials (Jayhawk) to finished pharma dosages (Bliss) — generating synergies and EPS accretion without further heavy capex. Whether that platform actually earns its cost of capital, and whether the long-deferred working-capital discipline finally arrives in FY27, are the open questions the next several quarters will answer. The market, at 89 times earnings, has already decided the answer is yes.

The Four Checks

1. Quality and moat. A decent business with a real but narrow edge, not a moat in the classic sense. The advantage is switching costs of a specific kind: once a global agro or pharma major qualifies Anupam’s multi-step process for a molecule and signs a 5–7-year contract, moving that molecule elsewhere is slow and expensive — hence the ₹14,000-crore contracted order book and customers willing to underwrite inventory through a downturn. Backward integration into fluorination via Tanfac adds a raw-material edge few Indian peers have. But the edge is contestable: the FY24–FY25 agrochemical downturn cut straight through to revenue and profit, top-10 customers were 81% of a recent quarter, and the returns the business actually earns (ROCE of 7.4%) suggest customers, not Anupam, hold most of the pricing power. Sticky relationships in a cyclical, capital-hungry trade — an edge, not a fortress.

2. Returns on incremental capital and runway. This is the weak check. ROCE has gone the wrong way as capital poured in — from a 13% peak in March 2022 to 9% in FY23–FY24 to 7.4% on the fresh snapshot, with ROE at 5.5% and a 3-year average of 4.6%. The ₹670-crore plant programme was sold at “incremental ROCE 20%+”; three years and a 65% revenue rebound later, blended returns are still below the cost of capital, and free cash flow has been negative in three of the last four years (−₹220 crore in FY26). The runway, to be fair, is genuinely there: management says the existing asset base can support ~₹3,500 crore of standalone revenue against ~₹1,676 crore today, capex is declared done, and the order book implies ₹1,700–1,800 crore of incremental annual revenue. If utilisation fills with only maintenance capex, incremental returns could finally look respectable — but that is a forecast, and the recorded history is large sums deployed at thin returns.

3. Capital allocation for the stage. Mixed, with the questionable side gaining weight. The build-phase logic was defensible — a contracted order book justifies plants — but the funding has leaned heavily on shareholders and lenders: a ₹500-crore QIP, a ₹550-crore preferential allotment, ongoing warrant conversions, and borrowings climbing from ₹822 crore (March 2023) to ₹1,867 crore (March 2026), with net debt heading toward ₹1,400–1,500 crore once Bliss closes. Dividends are token (~10% payout, 0.06% yield); no buyback history is visible in the data. The sharper concern is sequencing: with core ROCE at 7% and working-capital promises repeatedly deferred, management has pivoted to a debt-funded acquisition spree — Jayhawk at 9x EBITDA via a clever non-voting Class B structure, then a controlling stake in Bliss GVS funded by ₹300 crore of NCDs — before the existing capital has proven it can earn its keep. Tanfac worked well as a template, which earns some benefit of the doubt, but buying growth on leverage while the base business yields 7% is not textbook.

4. Price. Demanding by any reading. As of the June 2026 snapshot, the stock trades at ₹1,269 — 85.5 times earnings and 4.3 times book — for a business earning 5.5% on equity with negative free cash flow, rising debt, and an FY26 profit flattered by a near-zero effective tax rate in the last two quarters (management itself guides ~25% ahead, which alone would take a meaningful bite out of reported earnings). The market is paying today for the full four-entity platform story — order book converting, Bliss utilisation tripling, synergies arriving, working capital finally falling — before any of it shows up in returns. Even granting the 65% revenue rebound and the 20–25% growth guidance, this is a price that needs everything to keep going right.

Sources

• Earnings-call transcripts read (4): Q2 FY26 (17 Oct 2025), the Jayhawk US-acquisition update (15 Dec 2025, a special call — not a results call), Q3 FY26 (14 Feb 2026), and Q4/FY26 (25 May 2026). All from screener/BSE-hosted filings.
• Annual reports read (high-signal sections + targeted full-text reads): FY23, FY24, FY25. The FY25 report extract did not capture the chairman’s/MD’s letters or MD&A narrative — FY25’s management framing is therefore inferred from the financial statements, BRSR and capital-structure notes, not quoted.
• Financial snapshot: screener.in (consolidated, ANURAS), logged-out session, fetched 2026-06-07.
• Research dump: vault/Sources/Earnings/Anupam Rasayan India Ltd/ (_profile_digest.md, _concall_digest.md, _ar_digest.md, raw transcripts, annual-report sections, _snapshot.json, _manifest.json). Not published.